DSpace Repository

PBEF1/NAmPRTase/Visfatin - A potential malignant astrocytoma/glioblastoma serum marker with prognostic value

Show simple item record

dc.contributor.author Reddy, P Sreekanth
dc.contributor.author Umesh, Srikantha
dc.contributor.author Thota, Balaram
dc.contributor.author Tandon, Ashwani
dc.contributor.author Pandey, Paritosh
dc.contributor.author Hegde, A S
dc.contributor.author Balasubramaniam, Anandh
dc.contributor.author Chandramouli, B A
dc.contributor.author Santosh, Vani
dc.contributor.author Rao, M R S
dc.contributor.author Kondaiah, Paturu
dc.contributor.author Somasundaram, Kumaravel
dc.date.accessioned 2012-03-07T06:02:12Z
dc.date.available 2012-03-07T06:02:12Z
dc.date.issued 2008-05
dc.identifier 1538-4047 en_US
dc.identifier.citation Cancer Biology & Therapy 7(5), 663-668 (2008) en_US
dc.identifier.uri https://libjncir.jncasr.ac.in/xmlui/10572/574
dc.description Restricted Access en_US
dc.description.abstract Malignant astrocytomas comprise anaplastic astrocytoma (AA; grade III) and Glioblastoma (GBM; grade IV). GBM is the most malignant with a median survival of 10-12 months in patients. Using cDNA microarray based expression profiling of different grades of astrocytomas, we identified several fold increased levels of PBEF1 transcripts in GBM samples. Pre-B-cell colony enhancing factor 1 gene (PBEF1) encodes Nicotinamide phosphoribosyltransferase (NAmPRTase), which catalyses the rate limiting step in the salvage pathway of NAD metabolism in mammalian cells. Further validation using real time RT-qPCR on an independent set of tumor samples (n = 91) and normal brain samples (n = 9), GBM specific higher expression of PBEF1 was confirmed. Immunohistochemical staining for PBEF1 on a subset of the above samples largely reinforced our finding. We carried out ELISA analysis on serum samples of astrocytoma patients to determine whether this protein levels would correlate with the presence of tumor and tumor grade. PBEF1 serum levels were substantially elevated in many of the AA and GBM patients. Statistical analysis of these data indicates that in patients with astrocytoma, serum PBEF1 levels correlate with tumor grade and is highest in GBM. Immunohistochemical analysis of an independent set of 51 retrospective GBM cases with known survival data revealed that PBEF1 expression in the tumor tissue along with its co-expression with p53 was associated with poor survival. Thus, we have identified PBEF1 as a potential malignant astrocytoma serum marker and prognostic indicator among GBMs. en_US
dc.description.uri http://dx.doi.org/10.4161/cbt.7.5.5663 en_US
dc.language.iso en en_US
dc.publisher Landes Bioscience en_US
dc.rights © 2008 Landes Bioscience en_US
dc.subject glioma en_US
dc.subject astrocytoma en_US
dc.subject glioblastoma multiforme en_US
dc.subject microarray en_US
dc.subject PBEF1 en_US
dc.subject serum marker en_US
dc.subject survival analysis en_US
dc.subject nampt en_US
dc.subject visfatin en_US
dc.subject prognosis en_US
dc.subject Colony-Enhancing Factor en_US
dc.subject Nicotinamide Phosphoribosyltransferase en_US
dc.subject Glioblastoma en_US
dc.subject Survival en_US
dc.subject Therapy en_US
dc.subject Cancer en_US
dc.subject Expression en_US
dc.subject Apoptosis en_US
dc.subject Profile en_US
dc.subject Genes en_US
dc.title PBEF1/NAmPRTase/Visfatin - A potential malignant astrocytoma/glioblastoma serum marker with prognostic value en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account